The US Food and Drug Administration (FDA) approved an extended-release buprenorphine injection, sold as Brixadi, as a treatment for moderate to severe opioid use disorder. The drug is available as a weekly or monthly formulation in varying doses, providing “a new option for people in recovery who may benefit from a weekly injection to maintain treatment adherence,” the FDA wrote in an announcement.
Source: JAMA Online First